| Price | 1.81 |
| Price Change Today | 0.00 (0.00%) |
| P&P rating | ![]() |
| Zacks Rank | 1 - STRONG BUY |
| Open Price | $0.00 |
| Previous Close | $1.81 |
| Daily Range | $0.00 - $0.00 |
| 52-Week Range | $0.90 - $3.30 |
| Volume | 0 |
| Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. | |




Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment